Data / Drug companies / Droxidopa
Droxidopa: 15 companies and 45 products in the FDA NDC directory
Droxidopa is listed in the FDA National Drug Code Directory by 15 companies, with 45 products in commercial distribution. 42 of the products (93.3%) are marketed under an abbreviated new drug application (ANDA), the generic route. The most common dosage forms are capsule, and the newest product started marketing on March 3, 2025.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Companies listing it
- 15
- Products
- 45
- Generic (ANDA) products
- 42 (93.3%)
- Application numbers
- 11
- Routes
- Oral
- Brand names
- Northera
- openFDA record search
- api.fda.gov
Companies that list droxidopa
Ranked by number of products. Finished drugs in commercial distribution.
| Company | Products | Main dosage forms | Main marketing category | Newest product started |
|---|---|---|---|---|
| Ascend Laboratories, LLC | 3 | capsule | Generic drugs (ANDA) | February 19, 2021 |
| Aurobindo Pharma Limited | 3 | capsule | Generic drugs (ANDA) | February 18, 2021 |
| Bionpharma Inc. | 3 | capsule | Generic drugs (ANDA) | October 1, 2021 |
| Camber Pharmaceuticals, Inc. | 3 | capsule | Generic drugs (ANDA) | August 9, 2021 |
| CivicaScript LLC | 3 | capsule | Generic drugs (ANDA) | March 3, 2025 |
| Golden State Medical Supply, Inc. | 3 | capsule | Generic drugs (ANDA) | February 18, 2021 |
| Lundbeck Pharmaceuticals LLC | 3 | capsule | New drug applications (NDA) | September 1, 2014 |
| Lupin Pharmaceuticals, Inc. | 3 | capsule | Generic drugs (ANDA) | September 24, 2021 |
| Major Pharmaceuticals | 3 | capsule | Generic drugs (ANDA) | February 19, 2021 |
| Novadoz Pharmaceuticals LLC | 3 | capsule | Generic drugs (ANDA) | February 19, 2021 |
| ScieGen Pharmaceuticals, Inc. | 3 | capsule | Generic drugs (ANDA) | February 18, 2021 |
| Slate Run Pharmaceuticals, LLC | 3 | capsule | Generic drugs (ANDA) | November 10, 2021 |
| Sun Pharmaceutical Industries, Inc. | 3 | capsule | Generic drugs (ANDA) | February 18, 2021 |
| Zydus Lifesciences Limited | 3 | capsule | Generic drugs (ANDA) | February 19, 2021 |
| Zydus Pharmaceuticals USA Inc. | 3 | capsule | Generic drugs (ANDA) | February 19, 2021 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Capsule | 45 | 100% |
Marketing categories
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 42 | 93.3% |
| New drug applications (NDA) | 3 | 6.7% |
Updated November 6, 2026. Read from US Food and Drug Administration, National Drug Code Directory (openFDA). CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.